BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
Eli Lilly has won U.S. Food and Drug Administration clearance for Onswik (insulin efsitora alfa-gobe), its first once-weekly basal insulin for adults with type 2 diabetes. The drug cuts the injection burden from about 365 doses a year to 52 and will be sold in the U.S. as prefilled KwikPens in two concentrations — U-500 and U-1000 — in the coming months. Lilly already sells daily insulins such as Basaglar, but this is its entry into the emerging weekly-basal category.
What happened: The approval rests on the QWINT program, four phase 3 trials that enrolled more than 3,400 adults with type 2 diabetes. In every trial, once-weekly Onswik met the primary endpoint of non-inferior A1C reduction compared with daily insulins glargine or degludec. In QWINT-1 (patients new to insulin), Onswik lowered A1C by 1.31% versus 1.27% for insulin glargine at 52 weeks. The overall safety profile was similar to daily basal insulins, and the U.S. approval is Onswik’s fourth global regulatory win after the EU, Mexico, and Japan. Notably, use in type 1 diabetes is not recommended after the QWINT-5 trial showed higher severe hypoglycemia with efsitora than with degludec.
Why it matters: Onswik is the second once-weekly basal insulin cleared in the U.S., behind Novo Nordisk’s Awiqli (approved in March 2026 and launched nationwide in August through more than 70,000 pharmacies). That opens a direct commercial battle between the world’s two diabetes giants in a brand-new category — the same Lilly-vs-Novo dynamic already playing out in oral obesity drugs this year. Because regulators saw comparable glucose control rather than superiority over daily insulin, the fight will be won on dosing convenience, device familiarity, pricing, and formulary placement. For investors, it adds a fresh growth driver to Lilly’s cardiometabolic franchise beyond the GLP-1 story.
What to watch: Lilly has not disclosed a U.S. list price or precise launch date. Novo lists Awiqli at $99 per package with patient-program pricing — a benchmark Onswik will need to answer. Watch U.S. prescription data over the next two quarters to see whether Novo’s roughly six-month head start translates into durable formulary share, and whether payers embrace weekly dosing as cost-saving.
Related reading: Eli Lilly Strikes $3.35B InnoCare Deal to Hunt New Drugs Across Five Targets — https://bullounge.com/forums/topic/eli-lilly-strikes-3-35b-innocare-deal-to-hunt-new-drugs-across-five-targets/
Sources:
- https://www.fiercepharma.com/pharma/lilly-brings-more-heat-novo-fda-nod-once-weekly-insulin-onswik
- https://www.medscape.com/viewarticle/fda-approves-efsitora-once-weekly-basal-insulin-injection-2026a1000zq4
- https://www.managedhealthcareexecutive.com/view/fda-approves-lilly-s-onswik-the-second-once-weekly-insulin
- https://www.zacks.com/stock/news/2996012/llys-onswik-wins-fda-nod-as-a-once-weekly-basal-insulin-for-t2d
- https://pharmadevicenews.com/eli-lilly-just-cut-basal-insulin-dosing-from-365-injections-to-52-can-onswik-catch-novo-nordisks-awiqli/
Will weekly dosing be enough to give Lilly the edge, or does Novo’s six-month head start make Onswik an uphill battle? Share your take in the comments.
Auto-posted by the Bull Lounge news desk.
Not financial advice.Log in to vote
